Traditionally, cell adhesion assays are performed in a manual workstation format using fluorescence-based readouts. Herein, the authors describe a label-free homogeneous assay to identify inhibitors of a4b7 integrin-mediated cell adhesion to its ligand, the mucosal addressin cell adhesion molecule (MadCAM), using the SRU BIND platform. The biosensor is optically based and comprises a subwavelength polymer grating. The assay was validated using standard compounds and an a4 blocking antibody and correlated very closely with the manual assay format when running a battery of test compounds of varying potencies. Cell adhesion was strictly dependent on the presence of divalent cations where Mg 2+ was greater than Ca 2+ at promoting cell adhesion. This homogeneous and label-free format exhibited low variability with a calculated Z′ of 0.6. In addition to measuring a4b7-mediated 8866 cell adhesion to MadCAM, the authors also demonstrate that this platform can measure adhesion of Jurkat cells expressing a4b1 to the vascular cell adhesion molecule. Thus, the SRU BIND platform is widely applicable to measuring cell adhesion events mediated by other integrins binding to their receptors in an assay format that is amenable to high-throughput screening. (Journal of Biomolecular Screening 2011;16:536-544) 
INTRODUCTION
I ntegrins are cell adhesion molecules that play an important role in a number of biological processes, including hemostasis and wound healing, cell migration and trafficking, cell differentiation, and immune responses. 1, 2 Integrins exist as heterodimers containing two noncovalently bound type I transmembrane alpha and beta subunits that both consist of an extracellular domain, a single-spanning transmembrane domain, and a short intracellular domain. 3 Integrins can and do exist in different conformations or activation states. Based on studies using crystallography, nuclear magnetic resonance (NMR), and electron microscopy, integrins can adopt a bent conformation (low affinity for substrate), an extended conformation with closed headpiece (intermediate affinity), and an extended conformation with open headpiece (high affinity). 4 These conformations are in equilibrium with each other, yet the equilibrium can be shifted by cytoplasmic signals by what is known as inside-out signaling. 5, 6 Platelet aggregation represents a well-studied example of inside-out signaling where, in the resting state of the platelet, a2b3 integrin is in a low-affinity conformation for its ligand, soluble fibrinogen. 7 Following platelet activation by agonists such as thrombin, adenosine diphosphate (ADP), or epinephrine, which signal through G-protein-coupled receptors (GPCRs), a2b3 integrin shifts to a high-affinity conformation for fibrinogen and platelet aggregation results. 8 A number of signal transduction pathways can converge to enhance integrin affinity for their ligands where it has been elegantly shown that talin binding to the integrin b tail is an essential final step in stimulating inside-out activation. 9 Inside-out-generated integrin conformational changes are also required for arrest of rolling leukocytes on vascular endothelium where endothelial-based chemokines binding to chemokine receptors (GPCRs) on lymphocytes rapidly enhance integrin adhesiveness. 10, 11 Integrins are bona fide signal-transducing receptors that convey information regarding local environment and adhesive state after engagement with their ligand in a process known as outside-in signaling. 12 Binding of the integrin to its ligand also stabilizes the extended conformation. Integrin ligands are multivalent, which facilitates integrin clustering, which has been shown to be important for outside-in signaling. 13 Integrin signaling serves to initiate or modulate pathways involved in proliferation, survival/ apoptosis, shape, motility, gene expression, and differentiation. 14, 15 Integrins are not always activated and in fact exist most of the time in an inactivated or off state. When integrins are not regulated or are constitutively in the activated state, pathological conditions can occur. For example, whereas platelet aggregation is an important part of wound healing, aberrant activation of platelets, mediated by activated aIIbb3 integrin, is a primary cause of arterial thrombosis. 16 Integrins facilitate the movement of immune cells to their site of action in a process called extravasation, 17 which consists of a tightly regulated orchestration of adhesion and then de-adhesion of immune cells to substrates and blood vessel walls. It has been shown that mutations in a4b7 integrin can modulate the extent of lymphocyte trafficking into the gut, thus providing a mechanism to explain the wide variation of immune responses in patients suffering from inflammatory disorders such as ulcerative colitis and Crohn's disease. 18 Finally, avb3 integrin is constitutively expressed on several malignant tumor cells where a correlation exists between level of avb3 integrin expression and tumor invasiveness, particularly in liver metastases and melanomas. 19 In terms of inflammatory diseases, antagonism of a4 integrin has been shown to be an effective therapy for multiple sclerosis (MS) and Crohn's disease, 20, 21 for which natalizumab, a humanized antibody against the a4 integrin subunit, was approved for both indications. The impressive efficacy of natalizumab provides unequivocal validation of a4 integrin as a tractable pharmaceutical target. 22 Animal models and early clinical data would support a4 antagonism as a target in other inflammatory diseases such as asthma, inflammatory bowel disease, and rheumatoid arthritis. 23 Despite the attractiveness of integrins as pharmaceutical targets, there is not a plethora of higher throughput and robust assays to measure their activity. Although plate-based fluorescence formats as well as fluorescence-activated cell sorting (FACS) have been successful for measuring cellular adhesion events, these assay formats either involve tedious manual manipulation that limits their throughput or use instrumentation that are not amenable to high-throughput screening (HTS). Herein, we describe a label-free, high-throughput, and robust assay to identify smallmolecule inhibitors of a4b7-mediated cell adhesion to 8866 cells.
MATERIALS AND METHODS

Reagents
The antihuman Fc antibody used for MadCAM capture (cat. I-6260) was obtained from Sigma (St. Louis, MO). Recombinant MadCAM engineered to contain an Fc region can be purchased from R&D Systems (Minneapolis, MN). In-house-produced MadCAM-Fc was expressed in HEK293 cells and purified with a Protein A column followed by gel filtration on a Superdex-75 column. Corning Costar 96-well enzyme immunoassay (EIA)/ radioimmunoassay (RIA) flat-bottom high-binding plates (cat. 3590; Corning, Corning, NY) were used for the manual cell adhesion assay. Titanium dioxide (TiO 2 ) 384-well plates were obtained from SRU Biosystems (Woburn, MA). 8866 and Jurkat cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD). Glutamine, penicillin, and streptomycin were all purchased from Gibco-Invitrogen (Carlsbad, CA). Fetal bovine serum (F0926) was obtained from Sigma. Calcein AM dye was purchased from Invitrogen (Carlsbad, CA). All other regents were acquired from Sigma.
Cell culture
8866 and Jurkat cells were cultured in RPMI 1640 media from Gibco-Invitrogen supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 50 IU/mL penicillin, and 50 mg/mL streptomycin. Cells were passaged twice/week at a 1:10 ratio of cell suspension to fresh media.
Description of BIND Reader
The SRU BIND Reader is a novel label-free plate-based reader that is ideally suited for cell-based assays. Similar to surface plasmon resonance biosensors, this technology also uses a change of index of refraction at the biosensor surface to measure molecular interactions. However, in contrast to other optically based biosensors, the SRU BIND technology uses photonic crystal biosensors composed of a subwavelength polymer grating coated with a high refractive index material (TiO 2 ). 24 The biosensor surface resonantly reflects a single wavelength that is modulated by the adsorption of biomaterial to the sensor surface. The SRU BIND Reader uses a collimated broad wavelength light source to illuminate the biosensor surface at the bottom of each well of a SBSstandard plate. Reflected light is collected and transmitted by an optical fiber to a spectrometer, which measures the wavelength of reflected light. In the case of cell adhesion assays, specific adherence of cells to the bottom of the coated biosensor causes a shift in the wavelength of reflected light, which is denoted as a shift in peak wavelength value (PWV). Cells that passively settle on the plate do not elicit PWV shifts to the same magnitude as cells that specifically adhere to matrix coated on the biosensor surface. Treatments to cells that strengthen or weaken adhesion will result in an increase or decrease in PWV shift, respectively. Passive settling is defined by the amount of PWV shift observed when cells settle on a bovine serum albumin (BSA)-blocked TiO 2 plate and is considered background.
SRU BIND adhesion assay format
The cell adhesion assay is a 2-day assay where on day 1, 8866 cells were split from the carrying flask using a 1:4 ratio of 8866 cell suspension to fresh medium and cultured overnight. TiO 2 -coated 384-well plates were hydrated in water and then washed with 20 mM HEPES (pH 7.4) containing 140 mM NaCl, 1 mM CaCl 2 , and 1 mM MgCl 2 (buffer 1). Plates were prepared for experimentation by incubating an antihuman Fc antibody diluted 1:500 in buffer 1 in the TiO 2 plate for 1.5 h. Plates were then blocked with buffer 1 that was supplemented with 4% heat-inactivated BSA for 1 h and washed with buffer 1, and unless otherwise noted, recombinant MadCAM, engineered to contain an Fc region, was incubated on the plate at a concentration of 0.15 mg/mL overnight at 4h°C.
On day 2, compounds starting at a top concentration of 2 mM were diluted with DMSO 1:3 using the Biomek 2000 Laboratory Automation Workstation from Beckman (Brea, CA). Compounds were then diluted 50 × with 20 mM HEPES (pH 7.4) containing 140 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , and 0.3% BSA (buffer 2) in a Costar #3363 V-bottom plate. 8866 cells were harvested, counted, and diluted with buffer 2 to a concentration of 8 × 10 6 cells/mL, and then equal volumes of 8866 cells, as well as compounds diluted in buffer 2, were incubated together for 30 min at room temperature. The SRU BIND plate was washed with buffer 1 and aspirated to remove any nonbound recombinant MadCAM, and then 25 mL of buffer 2 containing 1% DMSO was added to the MadCAM-coated TiO 2 plate, and a prescan baseline measurement was recorded on the SRU BIND Reader. To initiate cell adhesion, 25 mL of the cell/compound mixture (60K cells/well final) was added to the MadCAM-coated TiO 2 plate, which represented a 200 × final dilution of compound. Kinetic measurements of PWV shift were then recorded by the SRU BIND Reader every 30 s up to 90 min unless otherwise noted. IC 50 values were calculated by defining 100% inhibition as the PWV shift observed when cells were pretreated with a saturating concentration (15 mg/mL) of the a4 blocking antibody (known as 21/6), where 0% inhibition (maximal cell adhesion) was defined as the PWV shift observed when cells were added alone to the MadCAM-coated well. All conditions contained a 1% DMSO final concentration in-well.
Manual cell adhesion assay format
On day 1, 8866 cells were prepared similarly as performed for the SRU BIND adhesion assay format. A Costar 96-well flatbottom plate was prepared for experimentation by immobilizing an antihuman Fc antibody diluted 1:500 in buffer 1 for 1 h. Plates were then blocked with buffer 2 and washed, and recombinant MadCAM was incubated on the plate at a concentration of 0.15 mg/mL in phosphate-buffered saline (PBS) supplemented with 0.9 mM CaCl 2 and 0.5 mM MgCl 2 overnight at 4 °C.
On day 2, 8866 cells were labeled with calcein-AM (10 mg/ mL) for 30 min at room temperature, and then cells were centrifuged at low speed to remove dye not captured in cells and then resuspended at 2 × 10 6 cells/mL in buffer 2. Compounds were prepared similarly as for the SRU BIND adhesion assay format where 100 mL of the cell/compound mixture was then added to the washed MadCAM-coated plate for 30 min at a final cell density of 100K cells/well. Plates were then carefully washed two times manually and then two additional times gently with a manifold. Cells remaining on the bottom of the plate were considered to have adhered to MadCAM, whereas cells that had been washed away were considered to be nonadherent. Adherence of cells to the MadCAM-coated plate was quantified by measuring the calcein fluorescence at the bottom of the plate using a Cytofluor 4000 plate reader from PerSeptive Biosystems (Framingham, MA) with excitation and emission wavelengths set at 485 and 530 nm, respectively, and gain at 47.
Description of BIND Scanner
The BIND Scanner enables high-resolution label-free imaging of cell attachment and adhesion signals. The BIND Scanner images a narrow segment of a photonic crystal optical biosensor at the bottom of a SBS-standard plate onto the slit of a custom imaging spectrometer. Changes in the strength and position of cell binding to the optical biosensor change the wavelength reflected back. At over a thousand individual points on the slit, the optical spectrum of the light reflected from the biosensor is measured, and the peak wavelength that is contained in the reflection is determined. From there, the point-to-point PWV is assembled into a line image, with lighter gray representing higher wavelength and darker gray representing lower wavelength. A mechanical translation stage scans the plate over the optics in a raster fashion, assembling successive line images into a full two-dimensional image of each well within a plate.
Imaging cell adhesion on the BIND Scanner
8866 cells incubated in the presence or absence of an a4 blocking antibody or compound 1 were then added to MadCAM-coated BIND plates at a density of 60 000 cells/ well. After 45 min, wells were read on the BIND Scanner to image cells that had adhered to MadCAM. A 1-mm 2 area was read by the scanner at a 3.75-mm resolution.
BIND Scanner data processing
The BIND Scanner software performs a smoothing on the data to remove background artifacts from causing false positives. The smoothed image is then thresholded (min/max for PWV shift). Any pixels that fall outside the min/max range are ignored. Pixels that are within the min/max range are checked against cell size parameters. A cell is defined as a continuous region of pixels. The size parameters identify the minimum and maximum sizes of a continuous pixel region that are then identified as a cell. Any pixels within the min/max threshold range that do not fall within the size parameters are ignored, resulting in only valid cell pixels. Pixels meeting cell parameters are pseudocolored for image clarity. The software calculates the strength of cell adhesion by first determining the average pixel value (PWV shift) for all the pixels within a well that were defined as a cell. The software then determines the average of the cell values to determine adhesion strength of the cells in a given well.
RESULTS
Monitoring adhesion of 8866 cells expressing a4b7 to MadCAM using the SRU BIND platform
8866 cells are a human B cell line that endogenously expresses the a4b7 integrin. a4b7 integrin has been characterized as a ligand for MadCAM where interaction of a4b7 integrin with MadCAM is important for lymphocyte homing to the gut. 25 In Figure 1 , we have examined the kinetics of 8866 cell adhesion to MadCAM. Upon addition of 8866 cells to a MadCAM-coated well, we observed a time-dependent increase in PWV shift, indicative of cell adhesion, which began to plateau at the 90-min time point. 8866 cells do not express a4b1 yet express high amounts of a4b7. We observed that the a4-specific antibody, 21/6, completely blocked the adhesion of 8866 cells to MadCAM in this assay, which would suggest that the PWV shift that was observed was not due to nonspecific or other protein-protein interactions but due predominantly to the interaction of 8866 cells with MadCAM ( Fig. 1) . In addition, a b7-specific antibody also blocked the interaction of 8866 cells to MadCAM in this assay (data not shown). A small amount of PWV shift was observed from the incubation of 8866 cells onto a well coated with only Fc antibody in the absence of MadCAM.
Determining the effect of cell density, Fc capture antibody, and MadCAM plating concentrations on assay performance
To better understand the parameters of the assay and to ensure that we are operating close to optimal assay conditions for screening compounds, we have investigated the effect of cell density, Fc capture antibody, and MadCAM plating concentrations on PWV shift. The recombinant MadCAM that we used in this study has an Fc tag that is strategically placed at its C-terminus as an N-terminal tag could affect proteolytic processing. Using this Fc tag, MadCAM could be specifically captured onto the SRU BIND plate in a manner that is optimal for binding a4b7 that is expressed on 8866 cells. In this assay, the Fc capture antibody was passively immobilized on the TiO 2 plate and then washed, followed by incubation with MadCAM overnight. In Figure 2 , we have titrated the Fc capture antibody concentration while keeping the MadCAM concentration constant at 0.3 mg/mL. Passively immobilizing a 1:500 dilution of Fc capture antibody into the TiO 2 plate to capture MadCAM markedly enhanced the PWV shift compared to the signal observed when cells would settle on BSA or passively coated MadCAM (0.3 mg/mL) alone (Fig. 2) . Dilutions of 1:4000 or greater of the Fc capture antibody resulted in a decreased PWV shift compared to lower dilutions. These data would suggest that the Fc capture antibody correctly orientates MadCAM, allowing optimal binding to a4b7 expressed on 8866 cells and subsequent cell adhesion.
Keeping the Fc capture antibody concentration constant at a 1:500 dilution, we next permuted the MadCAM concentrations to identify an optimal concentration range. Applying concentrations of MadCAM from 0.6 to 0.075 mg/mL in-well yielded similar signals where we began to observe a drop in PWV shift at 0.038 mg/mL concentration of MadCAM (see Supplemental Figure S1 ). For future experiments, we chose either 0.075-or 0.15-mg/mL concentrations of MadCAM, which ensured maximal signal to background.
Another parameter of relevance to investigate was the final cell density in the well where we added 10, 20, 40, 60, 80, and 120 × 10 3 cells to MadCAM-coated wells and plotted PWV shift at the 45-min time point. We observed a linear increase in PWV shift with increasing concentration of 8866 cells/well, which began to plateau at the 80 × 10 3 cells/well density (Supplemental Figure S1B) . The 60 × 10 3 cells/well density was chosen for future experiments as it represents a compromise between a reasonable signal and the extra cell culture burden required for using higher cell densities.
Metal dependency of a4b7 interaction with MadCAM
Divalent cations have been shown to regulate the affinity of integrins for their ligands. More recently, crystallographic studies have revealed the absolute requirement of divalent ions for ligand binding where the affinities of these interactions were differentially regulated by Mg 2+ , Ca 2+ , and Mn 2+ . 26 In Figure 3, we have investigated the effects of Mg 2+ and Ca 2+ ions in their ability to regulate adhesion of a4b7-expressing 8866 cells to a MadCAM-coated TiO 2 plate. We observed that Mg 2+ alone was more effective in promoting adhesion than Ca 2+ at each concentration tested (Fig. 3) .
Dose-response curves generated using a standard smallmolecule inhibitor of 8866 cell adhesion to MadCAM
To help validate our assay, we measured the kinetics of 8866 cell adhesion to MadCAM in the presence of increasing concentrations of compound 1, a standard inhibitor of a4b7mediated cell adhesion to MadCAM (Fig. 4A ). In this experiment, the PWV shift of 8866 cells, in the presence of increasing concentrations of compound 1, was recorded at 5-min intervals where we observed that compound 1 dose-dependently inhibited adhesion of 8866 cells to MadCAM. Choosing the 45-min time point for endpoint analysis, which is in the linear region of the PWV shift in this assay, we generated a dose-response curve characterized by an IC 50 for inhibition of 8866 cell adhesion of 238 nM (Fig. 4B ). This value compared closely to the IC 50 of 430 nM that was generated using the manual cell adhesion assay format (data not shown).
Correlation and variability between manual and SRU BIND assay formats
Currently, most assays to monitor cell adhesion are performed in a manual workstation mode, whereas the SRU BIND assay is performed in a label-free homogeneous format that records PWV shift as a readout parameter. One component in validating data generated using a novel technology platform is to compare them to data generated using an established standard format. In Figure  5A , we have taken a battery of compounds exhibiting low, medium, and high potency in the manual cell adhesion assay format and compared these IC 50 values to those obtained with the SRU BIND assay format. A correlation plot between IC 50 values calculated using the two formats yielded a correlation coefficient of 0.86. We also quantified variability in terms of Z′ between manual and SRU BIND formats where the Z′ value for the SRU BIND format was calculated to be 0.61, and the Z′ for the manual format was 0.56. Assay consistency with the SRU BIND format was investigated by testing the same battery of compounds on two different test occasions where we observed a correlation coefficient of 0.87, as shown in Figure 5B . The one circled point in Figure 5B was the result of a compound that we later found to be unstable when kept at -20 °C.
Applicability of the SRU BIND platform to measuring a4b1 adhesion to the vascular cell adhesion molecule
Although the SRU BIND platform has demonstrated excellent utility in measuring the adhesion of 8866 cells expressing a4b7 to MadCAM, we wanted to determine whether this technique could also measure cell adhesion of other integrins to their binding partners. Thus, we have immobilized vascular cell adhesion molecule (VCAM)-Fc onto a TiO 2 BIND plate similar to how we have captured MadCAM onto the TiO 2 -coated biosensor. Jurkat cells endogenously express a4b1, which has been shown to interact strongly with VCAM, which is thought to mediate T cell infiltration into the central nervous system (CNS). 21, 25 Upon addition of Jurkat cells into the VCAM-coated well, we observed a timedependent enhancement of PWV shift indicative of cell adhesion, which began to plateau after 60 minutes (Fig. 6 ). In contrast, we observed only a small increase in PWV shift when 8866 cells were added to wells coated with BSA or Fc capture antibody alone (Fig.  6) . The interaction of Jurkat cells with VCAM was completely blocked with an a4 blocking antibody at 15 mg/mL concentration (data not shown).
Imaging of cell adhesion and attachment with the SRU BIND Scanner
The SRU BIND Scanner allows for imaging of cells at the biosensor surface. Imaged cells are shown as light blue spots in Figure 7A . In row 1, compound 1 dose-dependently decreased the number of light blue spots imaged. Similarly, an a4 blocking antibody also dose-dependently decreased the number of cells imaged by the scanner (data not shown). Row 2 illustrates background levels of imaged cells in the absence of MadCAM. We would expect that in the absence of MadCAM, we should observe a similar amount of cells to be imaged at different compound concentrations, which is what we observed (Fig.  7A, row 2) . For all objects that were determined to be cells and imaged by the scanner in a well, cell adhesion strength, which is defined by the intensity of the object imaged, was determined for each cell and averaged in a well. A dose-response curve of cell adhesion strength was calculated from each concentration of compound 1 used in Figure 7A and plotted in Figure 7B . Compound 1 dose-dependently decreased cell adhesion strength with an IC 50 of 340 nM. The question remains whether cells that are imaged by the scanner represent cells that have passively settled onto the surface or mostly cells that have adhered to MadCAM. Using data obtained from brightfield analysis, we determined by manual counting that the number of cells that have settled onto the surface of the biosensor is the same whether or not compound 1 or a4 blocking antibody is present (Supplemental Figure S2 and data not shown), suggesting that the scanner predominantly images cells that have adhered to MadCAM.
DISCUSSION
There can be an advantage to developing screening assays that recapitulate as close as possible the relevant in vivo biology of the system that you are attempting to model. T cells expressing a4b7 are directed into the gut as a result of the interaction of a4b7 with the gut lining, which expresses MadCAM. In this article, we have described a label-free, homogeneous, functional cellular assay measuring a4b7-mediated cell adhesion of 8866 cells to MadCAM in a format that is amenable to HTS. This cell-based functional screening assay could represent an advantage over non-cell-based biochemical assays in identifying compounds that block the interaction of a recombinant expressed a4b7 integrin with MadCAM. This system has shown the potential for wide applicability in measuring integrin-based cell adhesion events where, in addition to measuring 8866 cell adhesion to MadCAM, we have also characterized the kinetics of Jurkat cell adhesion to VCAM ( Fig. 6 ). Aberrant cell adhesion caused by activation of integrins can play a role in mediating a number of pathologies, including coronary heart disease, cancer, and inflammatory diseases. 25 Thus, the applicability of this technique toward measuring adhesion in different cellular systems with different integrins and their binding partners could pave the way for the identification of new classes of integrin antagonists in the future.
The high degree of correlation between the SRU BIND format and the manual assay format in running a battery of standard and negative control compounds suggests that this novel platform offers a reliable readout for measuring cell adhesion and inhibition by small molecules (Fig. 5A,B) . Similar to what has been shown by other investigators using other manual assay formats, 26, 27 divalent ions were shown to dramatically affect cell adhesion in this assay as well ( Fig. 3 ). Although the calculated Z′ values for both assays were comparable, we did observe less variability in IC 50 determinations using the SRU BIND format for some historically problematic compounds that yielded inconsistent IC 50 determinations using the manual assay format (data not shown).
The readout parameter for the label-free SRU BIND format is PWV shift. How does a shift in PWV reflect cell adhesion? Some insight into answering that question is provided by the data in Figure 7A , generated using the SRU BIND Scanner, which shows images of 8866 cells at the biosensor surface. The BIND Scanner essentially takes a point-by-point PWV determination of cells in the well and converts that data to a line image. Compound 1 and an a4 blocking antibody dose-dependently decreased the number of imaged cells (Fig. 7A and data not shown) . In contrast, images created using brightfield analysis show that an approximately equal number of cells have settled onto the biosensor surface, whether blocking antibody or compound was present or not (Supplemental Figure S2 ). The images in Figure  7A and Supplementary Figure S2 would suggest that the large PWV shift measured by the biosensor on the SRU BIND Reader after addition of 8866 cells to MadCAM-coated wells (Fig. 1) is predominantly due to cellular adhesion events mediated by a4b7 interaction with MadCAM and not passive settling onto the biosensor, which does not elicit as large a magnitude of response or signal in this assay format.
Integrin signaling is closely coordinated and linked to growth factor signaling, where both pathways can modulate common signal transduction components. Activation of the canonical Ras-Raf-Mek-ERK pathway by growth factors is modulated or enhanced by integrins. 28, 29 Similarly, GPCRs, receptor tyrosine kinases (RTKs), and ion channels have been shown to modulate integrin affinity in what is known as insideout signaling. 5, 6 Both the SRU BIND and impedance-based label-free systems have been shown to be successful in measuring responses to GPCRs in agonist or antagonist modes. 30 By analogy to what we have observed in this study, PWV shifts that occur as a result of GPCR or ion channel modulation most likely result, in part, from GPCR-induced alterations of cellular adhesion at the biosensor surface. Thus, this platform could be useful for measuring activation or inhibition of any signaling pathway that can modulate the integrin system.
Thus, here we have developed a robust, label-free, and homogeneous assay to measure cellular adhesion of a4b7expressing 8866 cells to MadCAM using the SRU BIND technology. This assay was validated using an a4 blocking antibody and standard compounds. This technology is widely FIG. 7. (A) Label-free imaging allows for visualization of cell adhesion and its inhibition by small-molecule antagonist. 8866 cells (60K cells/ well) were added to a MadCAM-coated TiO 2 plate in the presence or absence of varying concentrations of compound 1 as indicated in the figure. After a 45-min incubation, images were recorded using the SRU BIND scanner. Cell images (light blue spots) were generated by thresholding the high-resolution, label-free signals measured on the BIND Scanner as described in Materials and Methods. In row 2, background 8866 cell binding to a plate coated solely with bovine serum albumin is shown. (B) Small-molecule antagonist compound 1 reduces the strength of cell adhesion of 8866 cells to MadCAM. 8866 cells incubated in the absence or presence of varying concentrations of compound 1 (as in A) were added to a MadCAM-coated BIND plate, and at the 45-min time point, the strength of cell adhesion was determined as described in Materials and Methods and plotted at the concentrations indicated to generate a dose-response curve. applicable to measuring cellular adhesion mediated by other integrins to their binding partners and is amenable to HTS and thus represents an alternative assay platform for cell adhesion assays that will allow for the identification of new compounds that will be of therapeutic benefit in inflammatory diseases and cancer.
